Showing results (591-600 of 1,351) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|December 23, 2024
A Phase 1, Open-Label, Randomized, Two-Part Study in Healthy Adult Volunteers to Evaluate the Bioavailability of the Maribavir Powder for Oral Suspension, as Well as Food Effect and Impact of RabeprazoleOlivia Campagne, Katarina Ilic, Andre Gabriel, et al.
Clinical Pharmacology in Drug Development|January 10, 2025
Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal AdenocarcinomaAlex Winning, William K Sietsema, Kristen K Buck, et al.
Clinical Pharmacology in Drug Development|January 9, 2025
A Comparative Analysis of the Pharmacodynamic and Pharmacokinetic Properties of 2 Controlled-Release Formulations Versus a Marketed Orlistat ProductStefan Grudén, Anders Forslund, Helena Litorp, et al.
Clinical Pharmacology in Drug Development|January 16, 2025
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin AspartSneha A Dongre, Gauri A Kulkarni, Damodar Thapa, et al.
Clinical Pharmacology in Drug Development|January 10, 2025
Determination of the Bioavailability of 3 Intranasal Formulations of Azelastine Hydrochloride in Healthy Male VolunteersJean Bousquet, Ludger Klimek, Mark Liu, et al.
Clinical Pharmacology in Drug Development|January 8, 2025
Impact of Sotorasib, a KRAS G12C Inhibitor, on the Pharmacokinetics and Therapeutic Window of Digoxin, a P-Glycoprotein SubstratePanli Cardona, Brett Houk
Clinical Pharmacology in Drug Development|January 6, 2025
Antipyretic Effect of Dexibuprofen Versus Ibuprofen in Children With Fever Caused by Upper Respiratory Tract InfectionChengsong Zhao, Lin Zhao, Juanjuan Xie, et al.
Clinical Pharmacology in Drug Development|December 11, 2023
Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer DiseaseEmmanuel O Fadiran, Edward Hammond, James Tran, et al.
Clinical Pharmacology in Drug Development|December 6, 2023
A Randomized, Single-Dose, Parallel-Controlled Phase 1 Clinical Comparison of an Omalizumab Biosimilar Candidate with Reference Omalizumab in Healthy Chinese Male VolunteersJie Cheng, Chenguang Wang, Jin Xu, et al.
Clinical Pharmacology in Drug Development|January 4, 2024
Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's WortKatja S Gümüs, Anna Teegelbekkers, Max Sauter, et al.
Pageof 136